PHARMACEUTICALS/BIO-TECH Five Key Manufacturing Challenges in Autologous Commercial Cell and Gene Therapies February 5, 2024 Paolo Siciliano, Cell and Gene Expert, PA Consulting, Martin Sowden, Pharma Supply Chain Expert, PA Consulting, Shanton Wilcox, U.S. Manufacturing Lead, PA Consulting, and Harry Ustik, CGT Manufacturing Expert, PA Consulting The personalized nature of autologous CGT results in complex manufacturing challenges, driving costs high when transitioning from clinical to commercial scale. Read More
Renault Group Acquires a Supply Chain Control Tower to Manage Transportation in Europe and BeyondTechnology